Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
99Tc-MDP Versus Celecoxib in Knee Osteoarthritis
NCT02993029Recruiting
- Sponsor
- Xinhua Hospital
- Start
- Sep 2017
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of technetium-99m-methylene diphosphonate in osteoarthritis (OA) (2 arms), sponsored by Xinhua Hospital. Primary endpoint: Pain, stiffness and joint function of knee at 12 months. Started Sep 2017; status: recruiting.
02
Drugs
technetium-99m-methylene diphosphonate
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02993029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02993029.